Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial.

@article{Bramhall2001MarimastatAF,
  title={Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial.},
  author={Simon Roderick Bramhall and Alexander Rosemurgy and P D Brown and C Bowry and John A. C. Buckels},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2001},
  volume={19 15},
  pages={3447-55}
}
PURPOSE The prognosis for unresectable pancreatic cancer remains dismal (1-year survival rate, < 10%; 5-year survival rate, < 5%). Recent advances in conventional chemotherapy and novel molecular treatment strategies warrant investigation. This, the largest randomized study in pancreatic cancer performed to date, compares marimastat, the first of a new class of agents, with gemcitabine. PATIENTS AND METHODS Four hundred fourteen patients with unresectable pancreatic cancer were randomized to… CONTINUE READING